misoprostol

Louisiana's 2024 law reclassified misoprostol as a controlled substance, requiring it to be stored securely and delaying access during emergencies. This has increased hemorrhage risks for pregnant patients, as misoprostol is a critical, cost-effective drug for treating postpartum hemorrhage and has other reproductive healthcare uses.

Louisiana's 2024 law reclassifying misoprostol as a controlled substance forced hospitals to store it securely, delaying access during emergencies. The drug is critical for treating pregnancy-related hemorrhages but is now harder to retrieve, increasing patient risk. The law also reclassified mifepristone, further complicating reproductive healthcare access.

Medicaid funding for Ohio’s reproductive health clinics, including Planned Parenthood locations, has resumed after a yearlong freeze that halted reimbursements for non-abortion services like STI testing and cancer screenings. Clinic closures in Hamilton and Springfield occurred during the freeze, with a 55% drop in family planning visits, disproportionately affecting communities of color. Telehealth services remain available to address access gaps.

A proposed California bill, AB 2540, would require community colleges with health centers to provide access to abortion pills starting in 2029 if funded, extending a 2019 law for public universities. Supporters argue it addresses access barriers for students, while campus health directors express concerns about funding and capacity.

A California bill would require community colleges with health centers to provide medication abortion starting in 2029 if the Legislature provides funding. The bill, AB 2540, follows a 2019 law for universities and aims to address access barriers, but health center directors note staffing and infrastructure challenges.

New laws in Iowa, Mississippi, and Tennessee restrict access to abortion medications and limit minors' access to sexual and reproductive healthcare, including the HPV vaccine. A federal lawsuit challenges FDA rules allowing mifepristone to be dispensed via telehealth, with nationwide implications.

New laws in Iowa, Mississippi, and Tennessee restrict access to abortion medications and HPV vaccines for minors, effective July 1. The laws require in-person dispensing of abortion pills and prohibit minors under 18 from consenting to STD-related vaccinations in Iowa. A federal lawsuit challenges FDA rules allowing telehealth dispensing of mifepristone, which could impact nationwide access.

New laws in Iowa, Mississippi, and Tennessee restrict access to abortion medications like mifepristone and misoprostol and limit minors' access to the HPV vaccine. A federal lawsuit challenges FDA rules allowing telehealth dispensing of mifepristone, with nationwide implications.

California is challenging claims by Heartbeat International and RealOptions Inc. that a progesterone-based treatment can reverse the effects of the abortion drug mifepristone. A trial in Alameda County Superior Court heard testimony from Dr. Mitchell Creinin, who stated there is no scientific evidence supporting the safety or efficacy of the abortion pill reversal protocol. The state seeks to stop the organizations from making false claims and impose fines.

Telehealth providers report that banning mifepristone, a key abortion pill, has not halted access as patients continue to receive misoprostol, the other drug used in medication abortions. Legal battles over mailing abortion pills persist, but experts argue widespread knowledge and distribution make restrictions ineffective.

Planned Parenthood is now offering abortion pills mifepristone and misoprostol in Washington state and Hawaii for residents to obtain preemptively and store at home in case they need to terminate a pregnancy in the future. This represents an expansion of medication abortion access in these two states.

Planned Parenthood is now offering abortion pills mifepristone and misoprostol in Washington state and Hawaii for residents to obtain and store preemptively in case they need to end a pregnancy in the future. This initiative allows individuals to have the medication available without needing to obtain a prescription at the time of use.

A study in the Journal of the American Medical Association found that patients experiencing miscarriage in states with abortion bans have fewer treatment options, including a shift away from the two-drug regimen of mifepristone and misoprostol toward less effective misoprostol-only treatments and increased expectant management. The study highlights risks like higher chances of hemorrhage and infection due to these changes.

A study found that pregnant patients experiencing miscarriage in states with abortion bans have fewer healthcare options, including a shift away from the recommended two-drug regimen (mifepristone and misoprostol) to less effective misoprostol-only treatments. The study also noted increased use of expectant management, which carries higher risks of complications.

A study published in the Journal of the American Medical Association found that pregnant patients experiencing miscarriage in states with abortion bans have fewer treatment options, including a shift away from the recommended two-drug regimen (mifepristone and misoprostol) to less effective methods. The study also noted increased use of expectant management, which carries higher risks of complications.

A study in the Journal of the American Medical Association found that pregnant patients experiencing miscarriage in states with abortion bans have fewer treatment options, including a shift away from the recommended two-drug regimen (mifepristone and misoprostol) to less effective misoprostol-only treatments and increased use of expectant management. The study highlights risks like hemorrhage and infection due to reduced access to standard care.